

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/162214 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61K 31/7088 (2006.01) A61K 31/713 (2006.01)
A61K 31/7115 (2006.01) A61P 25/28 (2006.01)
A61K 31/712 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2025/074542

(22) International Filing Date:

24 January 2025 (24.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2024/074611

30 January 2024 (30.01.2024) CN

PCT/CN2024/122340

29 September 2024 (29.09.2024) CN

(71) Applicant: SHANGHAI ARGO BIOPHARMACEUTI-
CAL CO., LTD. [CN/CN]; J2026, Room 1_203, 337 Shahe
Road, Jiangqiao Town, Jiading District, Shanghai 201803
(CN).

(72) Inventors: SHU, Dongxu; Room 201, No.24, Lane 535,
Qingnian Road, Qiutai Town, Yinzhou District, Ningbo,
Zhejiang 315100 (CN). SHAO, Pengcheng Patrick; 631
Addison Way, Warrington Township, Pennsylvania 18976
(US). XIA, Shiwei; Minqiang Village Lishan Town, Fuyang
District, Hangzhou, Zhejiang 311400 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SYNUCLEIN ALPHA (SNCA) GENE

(57) Abstract: Compositions and methods useful to reduce expression of synuclein alpha (SNCA) gene and for treatment of SNCA-as-
sociated diseases and conditions are provided. Provided are SNCA dsRNA agents, compositions or cells comprising SNCA dsRNA
agents, that can be used to reduce SNCA expression in cells and subjects.

WO 2025/162214 A1